Trial
NCT02716805
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Phase ITERMINATEDREGULATORYConfidence: HIGH
Sponsor
Ludwig Institute for Cancer Research
Collaborators
MedImmune LLC; Cancer Research Institute, New York City; Multiple Myeloma Research Foundation
Condition
Multiple Myeloma
Intervention
Tremelimumab
Why stopped
FDA placed on partial hold due to additional data
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-12